Kelly Brady
Executive VP & COOMs. Kelly Brady, M.S., is Chief Operating Officer of Seres Therapeutics, Inc. from March 02, 2026 and served as Senior Vice President of Clinical Development from 2025 to 2026 and serves as its Executive Vice President since March 02, 2026, overseeing Clinical Operations, Data Management and Biostatistics. Throughout her career she has held positions of increasing responsibility for global clinical operations, data management, pharmacovigilance operations and clinical program management within indications of oncology, infectious disease and cellular therapies. At Seres, Kelly held the position of program lead during the clinical trial execution and BLA for SER-109 (VOWST). Prior to joining Seres, she was Senior Director and Global Clinical Program Lead at Akebia Therapeutics, Inc., where she oversaw pivotal programs in anemia due to chronic kidney disease. She also previously held roles in Operations and Program management at Acetylon Pharmaceuticals, Inc., where she worked on the company’s acquisition by Celgene Corporation. Prior to Acetylon, she was a Global Phase 3 Clinical Operations Leader at Millennium Pharmaceuticals, Inc. (later Takeda Oncology), leading pivotal global oncology trials. She was a member of the operations team at Osiris Therapeutics, Inc., managing global GVHD studies for stem cell therapy, Prochymal. She holds a BS in Neuroscience from Lafayette College and a MS degree in Biotechnology from Johns Hopkins University.
Positions
- Company NameSeres Therapeutics, Inc.Stock CodeMCRBPositionExecutive VP & COOColleagues
- RNRichard N. KenderInterim CEO & Executive Chair
- MRMatthew R. HennPresident & Chief Scientific Officer
- TJThomas J. DesRosierExecutive VP, Chief Legal Officer & Secretary
- CMChris McChalicherExecutive VP & CTO
- KCKurt C. GravesIndependent Director
- WHWillard H. DereIndependent Director
- SAStephen A. BerensonIndependent Director
- EDEric D. ShaffDirector
